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E-mail address: eleygue@cc.umanitoba.ca (E. LeygThe steroid receptor RNA activator gene (SRA1) encodes for a functional RNA (SRA) as well as a pro-
tein (SRAP). While several groups reported on SRA-RNA mechanism of action, SRAP exact function
remains to be elucidated, mainly due to a lack of studies investigating the function of the protein
independently of its RNA counterpart. Using two independent models to examine its speciﬁc func-
tions, SRAP was found to enhance estrogen receptor alpha activity in a ligand and response-element
dependent manner. Our data therefore suggest that both transcript and protein products of the
SRA1 gene co-modulate the transcriptional activity of steroid receptors.
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The steroid receptor RNA activator (SRA) was characterized as a
non-coding transcript co-activating steroid receptors [1], nuclear
receptors [2–4] and the myogenic differentiation factor MyoD
[5]. In vivo experiments showed that a decrease in SRA expression
lead to a phenotype of myocardial contractile dysfunction in a zeb-
raﬁsh model [6], whereas an increase in mouse mammary gland
stimulated proliferation and apoptosis [7]. Altogether, SRA is sus-
pected to participate in normal and pathological events such as tis-
sue differentiation and tumorigenesis.
SRA acts embedded in ribonucleo-protein complexes recruited
at the promoter of target genes [1,8–10]. The ribonucleotide re-
gions involved in SRA/protein interactions have been mapped to
multiple predicted loops within the SRA core sequence [8,11].
SRA core (exon-2 to exon-5) deﬁnes the sequence necessary and
sufﬁcient for its co-activating function [1]. Lanz et al. showed that
silent mutations, which alter the predicted folding of speciﬁc loopschemical Societies. Published by E
; SRAP, steroid receptor RNA
substructure
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ue).(STRs), decrease SRA ability to co-activate the progesterone recep-
tor (PR) activity [11]. In particular, mutations (SDM1 and SDM7) in
the predicted substructures STR1 and STR7 almost suppressed SRA
activity (Fig. 1A).
Several alternatively spliced SRA transcripts have now been
characterized, differing from the originally identiﬁed SRA-RNA by
an extended 50 extremity [9,12,13]. In particular, we have identi-
ﬁed coding SRA transcripts, where exon-1 harbors a methionine
codon initiating an extended reading frame terminated in exon-5
[14]. The corresponding 236 amino-acids long protein (SRAP) has
been detected in multiple tissues and cell lines [15]. SRAP peptides
are differentially expressed in breast tumor tissue [16,17] and their
expression is associated with a poor prognostic in speciﬁc patients
subsets. This raises the possibility that SRAP might also be involved
in breast cancer progression.
Little is known about SRAP putative functions. It has nonethe-
less been proposed that SRAP physically interacts with the andro-
gen receptor and increases its activity in prostate cells [18,19].
More recently, Borth et al. reported that CT441, a Chlamydial pro-
tease, interacted with SRAP and had the ability to retain this pro-
tein in the cytoplasm [20]. They proposed that a decrease in
estrogen activity might result from this sequestration of SRAP out-
side the nucleus. Inversely, a decrease in estrogen receptor activity
was observed in breast cancer cells stably transfected with codinglsevier B.V. All rights reserved.
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Fig. 1. Modelization of SRA secondary substructures of the wild-type (WT) and STR 1 and 7 mutated (SRA SDM1/7) SRA sequences. (A) SRA substructures were visualized
using the mfold software. (B) Schematic diagram representing the different SRA constructs designed to discriminate between SRA and SRAP functions. (C) Western blot
analysis of HeLa cells transiently transfected with the constructs described in (B).
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tein, might therefore regulate the activity of steroid receptors. It
should however be stressed that many coding-SRA sequences used
in previous studies contained an intact core sequence. The possibil-
ity that SRA-RNA itself could participate in the effect potentially
attributed to SRAP cannot therefore be discarded.
To establish whether SRAP has the potential, independently of
its RNA, to modulate the activity of steroid receptors, we herein
have used two different approaches.2. Materials and methods
2.1. Plasmids used
The pS2-ERE-luciferase and PR-ERE-luciferase vectors were
kindly provided by Dr. Klinge [21]. The vitellogenin-ERE-luciferase
reporter construct and the PCDNA-V5-his-SRA1 (SRA-WT) con-
struct were previously described [16]. Sequences of EREs can be
found in Supplementary data. The site directed mutants, namely
1176 S. Chooniedass-Kothari et al. / FEBS Letters 584 (2010) 1174–1180SRA-RNA, SRA-PRO and SRA-NEG were generated by using syn-
thetic oligonucleotides and the Quick change site directed muta-
genesis kit (Stratagene, la Jolla, CA) using the SRA-WT vector as
template following manufacturer’s protocol. The oligonucleotides
sequences are outlined in the Supplementary data section. SRA-
NEW vector sequence is outlined Fig. 3A. This construct was com-
mercially generated by GeneCopoeia Inc (Rockville, MD).2.2. Cell culture and luciferase assays
Human cervical cancer (HeLa) cells were grown in DMEM sup-
plemented with 5% FBS. Transfection experiments were performed
as previously described [18]. Detailed protocol and statistical anal-
ysis are described in the Supplementary data section.0
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Fig. 2. SRAP differentially upregulates unbound and agonist/antagonist bound
estrogen receptor alpha activity in an ERE dependent manner. (A) Hela cells were
co-transfected with the PR-ERE-luciferase reporter vector together with the SRA
constructs illustrated in Fig. 1B as described in the materials and method section.
Bars and stars represent standard deviations and  and  represent signiﬁcant
(Student’s t-test, P < 0.05) difference with EV control or SRA-NEG, respectively. (B)
Same experimental procedure as in (A) but using the pS2-ERE-luciferase vector. (C)
Same experimental procedure as in (A) but using the vitellogenin-ERE-luciferase
vector.2.3. Western blot analysis
Total cell lysates were analyzed by Western blot analysis.
Transfected SRAP-V5 was detected using a mouse anti-V5 antibody
in conjunction with a goat anti-mouse HRP (Sigma, St Louis, MO)
antibody at dilutions of 1/5000 and 1/3000 respectively.
2.4. Low resolution structure modeling and sequence analysis
Michael Zuker’s Mfold program (http://mfold.bioinfo.rpi.edu)
was used to generate low resolution structure models. Computed
SRA sequences corresponded to the exact coding sequence used,
starting at the ﬁrst ATG (exon-1) and ended at the TAA stop codon.
The maximum distance allowed between paired bases was as-
signed to 54 bases.
3. Results and discussion
As outlined earlier, Lanz et al. showed that two series of silent
mutations (SDM1 and SDM7) drastically reduced SRA-RNA ability
to co-activate PR [11]. We exploited this property and designed
four distinct SRA constructs allowing the discrimination between
SRA-RNA and protein functions (Fig. 1B). SRA Wild-type construct
(SRA-WT) possesses an unmodiﬁed SRA sequence, from the ﬁrst
initiating ATG codon in exon-1 (61 nucleotides upstream of
exon-2) to the stop codon in exon-5. SRA-WT is therefore able to
encode for a functional RNA (intact core) as well as for the SRAP
protein. SRA-protein construct (SRA-PROT) contains a SRA se-
quence modiﬁed with the previously described series of silent
mutations SDM1 and SDM7. This construct, whose functional
RNA should be impaired, however encodes for SRAP. SRA-RNA en-
codes for a wild-type SRA sequence where the ﬁrst two ATG are
mutated to TTG in order to lose the ability to encode for SRAP. This
construct encodes for a functional RNA but no SRAP protein. The
fourth construct, SRA-NEG contains both mutated initiating codons
as well as SDM1 and SDM7 mutations. This construct should en-
code for a functionally altered RNA unable to produce SRAP. All
four SRA constructs contained a C-terminal V5 epitope in frame
of the SRAP coding sequence in order to monitor for protein coding
capacity.
Upon transient transfection, we detected the expected SRAP-V5
protein (36 Kda) solely in cells transfected with the two SRAP cod-
ing constructs, namely SRA-WT and SRA-PRO (Fig. 1C). No other
proteins were detected that might have been initiated at any of
the downstream ﬁve ATG codons present in SRA core sequence.
The effect of each of these constructs on ligand dependent
estrogen receptor alpha transcriptional activity has then been as-
sessed by measuring luciferase activity driven by three different
estrogen receptor responsive elements (EREs). Elements chosen,
found in human PR, human pS2, and Xenopus laevis vitellogeninA2 genes are known to be recognized by E2-bound estrogen recep-
tor with increasing afﬁnity; Kd = 3.3 ± 0.3 nM, Kd = 1.6 ± 0.02 nM,
and Kd = 0.11 ± 0.02, for PR-ERE, pS2-ERE and Vit-ERE, respectively
[21].
In the absence of ligand, noneof the SRAconstructs had any effect
on the luciferase activity drivenby PR-EREor pS2ERE (Fig. 2A andB).
In contrast, when investigating vitellogenin-ERE driven reporter
activity, cells co-transfected with SRA-WT, but not with other con-
structs, had a signiﬁcantly (P = 0.02) higher basal ESR1 activity than
cells transfected with empty vector (Fig. 2C). This suggests that the
co-expression of SRAP and its functional RNA can lead, on speciﬁc
EREs, to a co-activation of ESR1 in the absence of ligand.
Upon estradiol treatment, cells co-transfected with SRAP encod-
ing SRA-WT or SRA-PROT had, for each ERE, a signiﬁcantly higher
ESR1 transcriptional activity (Student’s T-test, two-sided,
P < 0.05) than cells co-transfected with empty vector (Fig. 2A–C).
For EREs with lower afﬁnity, namely PR-ERE (Fig. 2A) and pS2-
ERE (Fig. 2B), this effect was not seen upon co-transfection with
non-coding SRA-RNA or SRA-NEG. The selective removal of the ﬁrst
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ties of the products of SRA-WT and SRA-PROT. These data ﬁt with
results obtained by Klinge et al. who found that SRA-RNA was un-
able to co-activate ESR1 pS2- nor PR-ERE driven activity [21]. These
results also establish that SRAP as opposed to SRA-RNA potentiates
Estrogen bound estrogen receptor transcriptional activity assessedSRA-WT     1-ATGACGCGCTGCCCCGCTGG
SRAP-NEW     1-ATGACAAGATGTCCAGCAGG
-- - - - -
SRA-WT     61-GGCAACAAGGAACGCGGCT
SRAP-NEW     61-GGAAATAAAGAAAGAGGGT
- - - - - -
SRA-WT      121-GCCGGCGGACCCAGGCGCT
SRAP-NEW 121-GCAGGAGGACCAAGAAGAT
- - - -- -
SRA-WT      181-CCCAGAGTCCCCGCATCAG
SRAP-NEW   181-CCAAGAGTACCAGCGTCTG
- - - - -
SRA-WT      241-TCAAGTAAGGCTCCCAGGT
SRAP-NEW   241-AGCAGCAAAGCACCACGAA
- - - - -- --
SRA-WT      301-ACAAGTTTCCCAGTCGAGT
SRAP-NEW   301-ACGTCATTTCCGGTAGAAA
---- - - - --
SRA-WT      361-GCATTGGAAGACTGCCGTG
SRAP-NEW   361-GCGTTAGAGGATTGTAGAG
- - - - -- -
SRA-WT      421-CTGGCACTGCTGCAGGAAC
SRAP-NEW   421-CTCGCGCTCCTCCAAGAGC
- - - - - -
SRA-WT      481-ATGGCTCTACTGGTGCAAG
SRAP-NEW   481-ATGGCACTTCTAGTACAGG
- - - - -
SRA-WT      541-CGCTCCCTCATGGTTGACC
SRAP-NEW 541-AGAAGCTTAATGGTAGATC
--- - - - -
SRA-WT      601-TTAATTGCAGAAAAGAGGA
SRAP-NEW   601-CTCATAGCCGAGAAACGAT
- - - - -- --
SRA-WT      661-GCCACAGCTGAGAAGAACC
SRAP-NEW 661-GCAACGGCAGAAAAAAATC
- - - - - -
SRA-WT
A
B
Fig. 3. A SRA-NEW sequence encoding solely for SRAP. (A) Alignment of the wild-type (W
(B) Modelization of the impact of these mutations on SRA-RNA structure.through the expression of these lower afﬁnity ERE-luciferase re-
porter vector.
Non-coding SRA-RNA and SRA-NEG construct however signiﬁ-
cantly enhanced estrogen liganded ESR1 activity measured on
the higher afﬁnity vitellogenin-ERE (Fig. 2C). The co-activation
seen in the absence of encoded protein conﬁrm that SRA, as anCCAAGCGGAAGTGGAGATGGCGGAGCTGTACGTGAAGCCG
ACAAGCAGAAGTAGAAATGGCAGAACTTTATGTAAAACCA
- - - - - - - - - - -
GGAACGACCCGCCGCAGTTCTCATACGGGCTGCAGACCCAG
GGAATGATCCACCCCAATTTAGCTATGGACTACAAACACAA
- - - - - ---- - - - - - -
CGCTGCTTACCAAGAGGGTAGCCGCACCCCAGGATGGATCC
CACTACTAACAAAAAGAGTTGCAGCTCCGCAAGACGGGTCA
- - - - - - - - - - - - - -
AGACTTCTCCTGGGCCTCCCCCAATGGGGCCTCCACCTCCT
AAACAAGCCCAGGACCACCACCGATGGGACCACCGCCACCA
- ---- - - - - - - - - - -
CCCCACCTGTGGGGAGTGGTCCTGCCTCTGGCGTGGAGCCC
GCCCGCCAGTAGGAAGCGGACCGGCAAGCGGAGTAGAACCA
- - - - - - - - ---- - - - -
CTGAGGCTGTGATGGAGGATGTGCTGAGACCTTTGGAACAG
GCGAAGCAGTAATGGAAGACGTACTAAGGCCATTAGAACAA
-- - - - - - - - - - - -
GCCACACAAGGAAGCAGGTATGTGATGACATCAGCCGACGC
GACATACGAGAAAACAAGTGTGCGACGATATATCCAGAAGA
- - - - - - - - - - --- - - -
AGTGGGCTGGAGGAAAGTTGTCAATACCTGTAAAGAAGAGA
AATGGGCAGGGGGGAAATTAAGCATCCCAGTGAAAAAACGT
- - - - - ---- - - - - -- -
AGCTTTCAAGCCACCGGTGGGACGCAGCAGATGACATCCAC
AACTAAGCAGCCATCGATGGGATGCGGCGGACGATATACAT
- ---- - - - - - - - - -
ATGTGACTGAGGTCAGTCAGTGGATGGTAGGAGTTAAAAGA
ACGTAACAGAAGTATCACAATGGATGGTGGGGGTAAAGCGT
- - - - ---- - - - - -- -
GTCTGTTTTCAGAGGAGGCAGCCAATGAAGAGAAATCTGCA
CTTTATTCAGCGAAGAAGCGGCAAACGAGGAAAAGAGCGCG
- - - ---- - - - - - - - ---- -
ATACCATACCAGGCTTCCAGCAGGC
ACACAATCCCGGGATTTCAACAAGC
- - - - - - - -
SRA-NEW
T) and the new artiﬁcial (SRA-NEW) sequence containing extensive silent mutations.
1178 S. Chooniedass-Kothari et al. / FEBS Letters 584 (2010) 1174–1180RNA, has the ability to co-activate ESR1 activity [1,21,22]. Surpris-
ingly, SRA-NEG construct, originally designed to encode for a non-
functional RNA, was still able to enhance estrogen bound ESR1
activity. Alterations in the STR-1 and STR-7 are therefore not sufﬁ-
cient to completely abolish SRA-RNA effects in this high afﬁnity
vitellogenin-ERE context. As previously shown for several co-acti-
vators, including SRA, it appears that co-activation abilities are
potentially linked to the binding afﬁnity of the receptor considered
[21]. Further studies are needed to clarify this issue. SRA-RNA ef-
fect does not allow to unequivocally establish whether SRAP has
the potential to co-activate vitellogenin-ERE driven estrogen
receptor activity. It should however be noted that the previously
described effect of SRA-WT only on ligand independent estrogen
receptor alpha activity (Fig. 2C, ethanol) suggests that a comple-
mentation might happen between RNA and protein activity.
We found that 4-OH-Tam had an agonistic effect and increases
ESR1 activity on both PR- and pS2-ERE reporter (Fig. 2A and B).
This agonistic effect was not signiﬁcantly modiﬁed by either
SRA-RNA or SRAP when assessing PR-ERE luciferase activityCD2
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Fig. 4. SRAP potentiates ESR1 transcriptional activity. (A) Schematic diagram of the new
by CD1 and CD2. NLS: nuclear localization signal. (B) Western blot analysis of HeLa cells tr
intact ATG and ATG mutated to TTG respectively. T1 and T2 refer to the 26 and 23 kDa tru
methionine 3 and 4 enhance ESR1 ligand dependant activity on the vitellogenin reporter v
NEG, Met-3 and Met-3 Neg and Met-4 and Met-4 Neg constructs respectively. Bars repres
with EV control.(Fig. 2A). In contrast, we found that constructs encoding for SRAP
(SRA-WT and SRA-PRO) but not SRA-RNA (SRA-RNA and SRA-
NEG) signiﬁcantly enhanced tamoxifen bound ESR1 activity as
compared to the empty vector and compared to SRA-NEG
(Fig. 2B). This suggests that SRAP has the ability to potentiate some
of the agonistic effects of tamoxifen. Interestingly, we have re-
cently shown that high expression of different endogenous SRAP
peptides in estrogen receptor positive breast tumors was a poor
prognostic marker in breast cancer patients treated with tamoxifen
[17]. It is therefore possible that SRAP peptides, through increasing
the agonistic tamoxifen action on selective ER target genes, might
contribute to a ‘‘more aggressive tumor phenotype”. Further stud-
ies are needed to establish the validity of this hypothesis.
To determine the exact contribution of SRAP on the co-activa-
tion of ESR1 effect on the vitellogenin-ERE reporter, we designed
a new extensively mutated artiﬁcial SRA sequence (SRA-NEW)
where silent mutations were introduced in every possible wobble
position (Fig. 3A). This led to a drastic change (Fig. 3B) in all pre-
dicted SRA secondary structures. SRA-NEW construct is thereforeRA-New
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encoding for SRAP. As control, a similar construct (SRA-NEW-NEG)
where the two initiating ATG codons have been mutated was
obtained.
Transient transfection led to a 36 kDa SRAP-V5 tagged protein
(Fig. 4B lane 1). Two additional fainter bands, migrating at 26
and 23 kDa, were also detected. Similar bands were detected when
cells were transfected with SRA-NEW-NEG (Fig. 4B lane 2). As de-
picted Fig. 4A, SRAP sequence contains seven in frame ATG codons.
We suspect that in the absence of the ﬁrst two ATGs, downstream
ATG codons can act as alternative start codons in this extensively
mutated SRA sequence. It should be noted that in the original
wild-type SRA sequence, this phenomenon does not occur
(Fig. 1C). A series of 50 deleted mutants starting at each in frame
methionine codon (MET-3 to MET-7) was generated (Fig. 4A). Cor-
responding negative controls were obtained by mutating the initi-
ating ATG to TTG. As shown Fig. 4B, mutating the third methionine
resulted in the loss of the 26 kDa protein but did not affect the
presence of the 23 kDa SRA protein. Only mutation of the fourth
ATG to TTG however led to the loss of this peptide.
Altogether, we believe that detected truncated proteins resulted
from the use of alternative starts at methionines 3 and 4. No
detectable protein starting from methionine 5, 6 or 7 was detected
(Fig. 4B and data not shown).
The effect of each of these constructs on ESR1 transcriptional
activity on vitellogenin-ERE was assessed as described earlier. Both
SRA-NEW and SRA-NEW-NEG signiﬁcantly enhanced ESR1 tran-
scriptional activity as compared to the empty vector (P = 0.0006
and P = 0.0001, respectively) (Fig. 4B panel 1). This suggests that
the full-length SRAP as well as the two shorter SRA peptides are
able to co-activate estradiol dependent ESR1 activity. SRA-MET-3,
SRA-MET-3-NEG and SRA-MET-4 indeed signiﬁcantly enhanced
estradiol dependent ESR1 transcriptional activity (P = 0.008,
P = 0.00008 and P = 0.01, respectively). Removal of the fourth
methionine (SRA-MET-4-NEG), which led to a loss of any detect-
able protein expression, also resulted in the suppression of ESR1
co-activation. SRA-MET-5, SRA-MET-6, and SRA-MET-7 did not ex-
press any detectable protein nor co-activate estradiol bound ESR1
transcriptional activity (data not shown). Overall, our results dem-
onstrate that SRAP can potentiates ESR1 activity on the vitello-
genin-ERE independently of SRA. Furthermore, the C-terminal
SRAP sequence starting from the fourth methionine is sufﬁcient
for this effect. In support of this hypothesis, Kawashima et al. have
shown that a short rat SRAP (starting at methionine 3) was able to
co-activate androgen receptor’s transcriptional activity [18]. As
shown Fig. 4A, the region sufﬁcient in potentiating ESR1 activity
contains the second conserved SRAP domain [9,15]. Interestingly,
this domain contains a nuclear localization (NLS) motif as well as
a LXXAL motif, shown on another nuclear receptor co-activator
NcoA62 to be responsible for its direct interaction with nuclear
receptors [23]. Further functional studies are needed to examine
the exact contribution of the NLS and the LXXAL motifs in SRAP’s
ability to potentiate E2 dependent ESR1 activity. It should be noted
that recent work by Borth et al. suggests that SRAP nuclear locali-
zation could be impaired by binding of SRAP to the Chlamydial pro-
tease CT441 [20]. These authors proposed that it might provide a
new way to address SRAP function independently of its RNA.
Overexpression of both SRA-RNA and protein in MCF-7 cells re-
sulted in a decreased ESR1 transcriptional activity as measured by
the same vitellogenin-ERE luciferase vector as the one used in this
study [16]. We had attributed the decrease in ESR1 activity to the
concomitant expression of both SRA and SRAP. The disparity in
SRAP function (repressor versus activator) observed between the
previous and current studies could be due to the difference in cell
lines used (MCF7 versus HeLa) and/or the transfection techniques
used (stable versus transient SRA transfection). Moreover, increas-ing evidence suggests that target gene promoter, tissue and cell
lines contexts can lead to functional inversion among co-regulators
[24]. As such, co-activators can become co-repressors and vice
versa.
In this study, we are for the ﬁrst time demonstrating that SRAP
increases ESR1 transcriptional activity independently of its RNA
counterpart. SRAP and SRA functions therefore appear intertwined
and both involved in the regulation of the same signaling pathway.
SRA1 gene belongs to a recently discovered class of genes encoding
both functional RNA and protein [25–27]. We will only understand
the full implication of such systems when both of their faces are
fully explored.
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